Skip to content
HowShorted

Atara Biotherapeutics, Inc. short interest in 2021

In 2021, Atara Biotherapeutics, Inc.'s disclosed short interest ran from 14.49% of shares outstanding on 15 Jan 2021 to 10.66% on 31 Dec 2021, a change of -3.83 percentage points. The year's high was 16.88% on 31 Mar 2021 and its low 9.83% on 30 Nov 2021, averaging 13.95% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.30 days on 13 Aug 2021. Full history: Atara Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Atara Biotherapeutics, Inc. in 2021

2021 in figures

Start of year
14.49% (15 Jan 2021)
End of year
10.66% (31 Dec 2021)
Change
-3.83 pp
High
16.88% (31 Mar 2021)
Low
9.83% (30 Nov 2021)
Average
13.95%
Highest days to cover
23.30 (13 Aug 2021)
SEC filings marked
8

Every report in 2021

Atara Biotherapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202114.49%14.38
29 Jan 202115.21%12.68
12 Feb 202115.10%17.94
26 Feb 202114.29%18.78
15 Mar 202115.07%13.7110-K filed, results (8-K)
31 Mar 202116.88%14.43
15 Apr 202116.08%19.89
30 Apr 202114.44%10.00
14 May 202115.20%14.7710-Q filed, results (8-K)
28 May 202115.10%18.46
15 Jun 202115.03%15.82
30 Jun 202113.87%10.82
15 Jul 202114.37%16.48
30 Jul 202115.41%22.97
13 Aug 202115.08%23.3010-Q filed, results (8-K)
31 Aug 202114.42%13.94
15 Sep 202114.72%19.71
30 Sep 202113.83%13.16
15 Oct 202112.94%11.32
29 Oct 202112.25%17.50
15 Nov 202110.16%9.9410-Q filed, results (8-K)
30 Nov 20219.83%11.97
15 Dec 202110.30%12.07
31 Dec 202110.66%10.24

See also: Atara Biotherapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.